The PEPCAD-DES study is one among the first studies investigating efficacy of PCB for treatment of in-DES-restenosis (3,4), but it is the only one having more than 50% of patients presenting with recalcitrant restenosis after implantation of at least 2 layers of stent. However, the observed TLR rate with PCB (15.3% at 1 year and 19.4% at 3 years) in this very complex population is still similar to the ones reported in other studies that included mostly patients with first in-DES restenosis (<22% at 1-year follow-up and up to 36% at 3-year follow-up) (2-5,8). In the ISAR-DESIRE 3 (Intracoronary Stenting and
Germany. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose. There are many possible explanations for these puzzling findings. First, differences in all-cause mortality rates were observed in both studies. Three-year cumulative all-cause mortality was 6.0% with PCB and 9.4% with POBA in the ISAR-DESIRE 3 study, whereas it was 8.3% with PCB and 13.2% with POBA in the PEPCAD-DES study (2) . For PCB-treated patients, this means an absolute annual mortality increase of 2% in the ISAR-DESIRE 3 study and of 3.5% in the PEPCAD- 
